Abstract
Chronic autoimmune and inflammatory diseases exhibit variable genetic factors. The tools for specific and efficient genetic engineering are developing at a dramatic pace and are now being applied to therapy of human diseases. Gene editing tools can be used to interdict the pathology of inflammation at multiple stages. Therapies utilizing genetically modified cells offer many potential advantages over traditional cellular therapy approaches. Monogenic autoinflammatory disease, loss of self-tolerance, autoimmune disease based in humoral immunity, and regenerative medicine for tissues deranged or destroyed by inflammation are potential pathologies that could be treated with therapies based in genetic editing technologies. In this review, we discuss the rapid evolution of technologies for genome editing and their applications for autoimmune and inflammatory diseases. We compare older-generation methods, including zinc-finger nucleases and transcription activator-like effector nucleases, with more-recently developed tools, mainly CRISPR/Cas9. Gene-editing tool delivery methods including viral vectors and non-viral technologies are summarized. Finally, pre-clinical experiments with gene editing for therapy of animal models of autoimmune and inflammatory disease, and initial experience with gene-edited cells in human autoimmunity are described. In this review, we discuss potential therapeutic uses of chimeric autoantigen receptor T cells and regulatory T cells for polygenic disease, genetically-modified hematopoietic stem and progenitor cell transplantation for monogenic disease, and modified induced pluripotent stem cells for regenerative medicine.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e1-e7 |
| Journal | Seminars in Arthritis and Rheumatism |
| Volume | 49 |
| Issue number | 1 |
| DOIs | |
| State | Published - Aug 1 2019 |
Fingerprint
Keywords
- Autoimmune diseases
- Autoimmunity
- Gene editing
- Inflammation
PubMed: MeSH publication types
- Journal Article
- Review
Cite this
A new era of genetic engineering for autoimmune and inflammatory diseases. / Ewart, Dave; Peterson, Erik J; Steer, Clifford J.
In: Seminars in Arthritis and Rheumatism, Vol. 49, No. 1, 01.08.2019, p. e1-e7.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - A new era of genetic engineering for autoimmune and inflammatory diseases
AU - Ewart, Dave
AU - Peterson, Erik J
AU - Steer, Clifford J
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Chronic autoimmune and inflammatory diseases exhibit variable genetic factors. The tools for specific and efficient genetic engineering are developing at a dramatic pace and are now being applied to therapy of human diseases. Gene editing tools can be used to interdict the pathology of inflammation at multiple stages. Therapies utilizing genetically modified cells offer many potential advantages over traditional cellular therapy approaches. Monogenic autoinflammatory disease, loss of self-tolerance, autoimmune disease based in humoral immunity, and regenerative medicine for tissues deranged or destroyed by inflammation are potential pathologies that could be treated with therapies based in genetic editing technologies. In this review, we discuss the rapid evolution of technologies for genome editing and their applications for autoimmune and inflammatory diseases. We compare older-generation methods, including zinc-finger nucleases and transcription activator-like effector nucleases, with more-recently developed tools, mainly CRISPR/Cas9. Gene-editing tool delivery methods including viral vectors and non-viral technologies are summarized. Finally, pre-clinical experiments with gene editing for therapy of animal models of autoimmune and inflammatory disease, and initial experience with gene-edited cells in human autoimmunity are described. In this review, we discuss potential therapeutic uses of chimeric autoantigen receptor T cells and regulatory T cells for polygenic disease, genetically-modified hematopoietic stem and progenitor cell transplantation for monogenic disease, and modified induced pluripotent stem cells for regenerative medicine.
AB - Chronic autoimmune and inflammatory diseases exhibit variable genetic factors. The tools for specific and efficient genetic engineering are developing at a dramatic pace and are now being applied to therapy of human diseases. Gene editing tools can be used to interdict the pathology of inflammation at multiple stages. Therapies utilizing genetically modified cells offer many potential advantages over traditional cellular therapy approaches. Monogenic autoinflammatory disease, loss of self-tolerance, autoimmune disease based in humoral immunity, and regenerative medicine for tissues deranged or destroyed by inflammation are potential pathologies that could be treated with therapies based in genetic editing technologies. In this review, we discuss the rapid evolution of technologies for genome editing and their applications for autoimmune and inflammatory diseases. We compare older-generation methods, including zinc-finger nucleases and transcription activator-like effector nucleases, with more-recently developed tools, mainly CRISPR/Cas9. Gene-editing tool delivery methods including viral vectors and non-viral technologies are summarized. Finally, pre-clinical experiments with gene editing for therapy of animal models of autoimmune and inflammatory disease, and initial experience with gene-edited cells in human autoimmunity are described. In this review, we discuss potential therapeutic uses of chimeric autoantigen receptor T cells and regulatory T cells for polygenic disease, genetically-modified hematopoietic stem and progenitor cell transplantation for monogenic disease, and modified induced pluripotent stem cells for regenerative medicine.
KW - Autoimmune diseases
KW - Autoimmunity
KW - Gene editing
KW - Inflammation
UR - http://www.scopus.com/inward/record.url?scp=85066078940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066078940&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2019.05.004
DO - 10.1016/j.semarthrit.2019.05.004
M3 - Review article
VL - 49
SP - e1-e7
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
SN - 0049-0172
IS - 1
ER -